We understand that what we do matters — to our patients, clinicians that use our products, our employees and the communities in which we live and work. Disease states that will be targeted include cardiovascular disease, diabetes, kidney failure and hernia. Products for various surgical specialties will also be targeted.
PTFE – POLYTETRAFLUOROETHYLENE, is a fully fluorinated polymer that has attributes of excellent chemical resistance, high temperature stability, and good non-stick properties. It is an extremely inert, lubricious material and after more than 30 years of use as an artificial blood vessel, remains the gold standard for synthetic substitutes. Vascular grafts can be used to bypass or replace diseased or damaged veins and arteries. PTFE grafts are typically highly porous allowing for tissue ingrowth. They continue to dominate in arteriovenous access and smaller caliber synthetic graft applications.
Introducing BIOVIC’s flagship product, the AVATAR® PTFE Vascular Graft. AVATAR® PTFE Vascular grafts are intended for use in arterial vascular reconstruction, segmental bypass and for arteriovenous vascular access. The AVATAR® graft is constructed from PTFE, a biomaterial with a long history of clinical use.
Designed and developed by BIOVIC engineers using their proprietary Humidity Resistant Technology (HRT) this graft either meets or exceeds the performance and handling characteristics of its competitors. Featuring an open, porous microstructure on both internal and external surfaces to maximize tissue in-growth and healing response, the The AVATAR® graft is also the base substrate used for the SPIRAL FLOW™ Graft.
In pre-clinical studies the AVATAR®™ graft was evaluated using a dialysis graft shunt model alongside competitor grafts. Histological analyses confirmed that the AVATAR® Vascular Graft performed on par, if not slightly better than the competition.
Comparative Testing: Comparisons in strength and handling were made between AVATAR® Vascular Grafts and commercially available competitive product. Results indicated that the AVATAR® Vascular Graft was equivalent in all respects. Feedback also suggested that the grafts were softer with better handling than the competition.
The AVATAR® PTFE Vascular Graft comes in dual barrier sterile packaging. It is currently available in 22 product codes.
VFT developed and patented its novel Spiral Laminar Flow™ (SLF) technology which restores the natural pattern of blood flow. It is focused on the Research & Development of vascular and endovascular devices with the application of this technology and also forging strategic partnerships with leading industry players. Vascular Flow Technologies (VFT) has also evolved into an ISO 13485 Medical Device Development company with unique insight and capabilities in pre-clinical development and testing.
Vascular Flow has developed a range of products using their 18 patent families based on their understanding of the benefits of Spiral Laminar Flow (SLF™).
VFT’s SLF™ technology is a unique and IP protected design which eliminates the turbulent blood flow seen in diseased vessels and standard prosthetic vascular grafts. By reintroducing the normal pattern of blood flow through the vessel, graft failure and complications for the patient are significantly reduced.
The efficacy of VFT's Spiral Flow™ Vascular grafts is supported by an ongoing program of clinical trials and an existing body of robust clinical evidence. The Surgeon has the benefit of a familiar, safe and clinically proven graft with the added power of Spiral Laminar Flow™ technology delivering:
Restoring natural blood flow...the body has evolved to utilize efficient and optimal processes. Blood flow in the body’s vessels is spiral in nature. VFT's Spiral Flow™ grafts are unique in construction from all other prosthetic vascular grafts, and are the ONLY grafts proven to induce Spiral Laminar Flow™, remodeling turbulent flow into the normal spiral pattern seen throughout the body.